Stock Analysis, Dividends, Split History

TRCH / Torchlight Energy Resources, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)66.56
Enterprise Value ($M)63.42
Book Value ($M)20.16
Book Value / Share0.29
Price / Book3.30
NCAV ($M)-12.57
NCAV / Share-0.18
Price / NCAV-5.30
Share Statistics
Common Shares Outstanding 63,640,034
Preferred Stock Shares Outstanding 0
Common Stock Shares Outstanding 63,340,034
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.05
Return on Assets (ROA)-0.07
Return on Equity (ROE)-0.13
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio2.27
Income Statement (mra) ($M)
Oil And Gas Revenue570,499.00
Production Revenue Receivable142,932.00
Other Sales Revenue Net0.00
Net Income-0.92
Earnings Per Share Basic And Diluted-0.02
Cash Flow Statement (mra) ($M)
Cash From Operations0.47
Cash from Investing-9.46
Cash from Financing-9.46
Identifiers and Descriptors
Central Index Key (CIK)1431959

Split History

Stock splits are used by Torchlight Energy Resources, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

[Opinion] Oil & Gas Firm Makes Progress at Its Orogrande Basin Project

2018-08-23 oilvoice
In an Aug. 16 research note, analyst John White with ROTH Capital Partners reported that Torchlight Energy Resources Inc. (TRCH:NASDAQ) gave a "positive" operational update on its Orogrande asset, whose large land package it is developing. "We are encouraged that Torchlight sees further potential and plans additional wells this year and into 2019," he wrote.

Torchlight Energy Confirms What Rich Masterson Always Knew, There's Gold In The Orogrande!

2018-08-06 seekingalpha
Torchlight has successfully confirmed the presence of a petroleum system in the Orogrande basin of West Texas. (3-0)

[Opinion] Oil & Gas Stock 'in Position to Start a Major Bull Market Advance'

2018-08-06 oilvoice
Technical analyst Clive Maund discusses why he believes the stock of a small oil and gas company actively exploring in West Texas is at a "near perfect entry point."

[Opinion] Torchlight Illuminates a New Texas Oil Basin

2018-08-01 oilvoice
Bob Moriarty of 321 Energy takes a look at what positive drill results in the Orogrande Basin in West Texas mean for the company.

[Opinion] Why Four Wall Street Experts Are Recommending This Oil Stock

2018-07-31 oilvoice
A small-cap oil and gas explorer is the first to pull significant hydrocarbons out of the Orogrande Basin in Texas, opening up a new field discovery.

CUSIP: 89102U103